GP IIb/IIIa inhibitors in NSTEMI: which statement is true?

GP IIb/IIIa inhibitors in NSTEMI: which statement is true?

• A. They replace DAPT
• B. Not routinely required in NSTEMI and are used mainly during PCI
• C. They are always given in NSTEMI
• D. They are contraindicated in all ACS

Answer: (B)

GP IIb/IIIa inhibitors are potent antiplatelet drugs that block the final common pathway of platelet aggregation at the GP IIb/IIIa receptor. In NSTEMI, the foundation of therapy is aspirin, a P2Y12 inhibitor, and anticoagulation. Because adding these inhibitors increases bleeding risk, they are not routinely given to every NSTEMI patient. They are used selectively, most often during percutaneous coronary intervention to reduce peri-procedural thrombotic events, or in high-risk NSTEMI patients with ongoing ischemia or large thrombus burden when PCI is planned. They do not replace dual antiplatelet therapy; DAPT plus anticoagulation remains the core, with GP IIb/IIIa inhibitors acting as an adjunct in the cath lab or in select medical scenarios. They are not universally contraindicated in all ACS; only in the presence of certain contraindications such as active major bleeding or severe thrombocytopenia.

GP IIb/IIIa inhibitors are potent antiplatelet drugs that block the final common pathway of platelet aggregation at the GP IIb/IIIa receptor. In NSTEMI, the foundation of therapy is aspirin, a P2Y12 inhibitor, and anticoagulation. Because adding these inhibitors increases bleeding risk, they are not routinely given to every NSTEMI patient. They are used selectively, most often during percutaneous coronary intervention to reduce peri-procedural thrombotic events, or in high-risk NSTEMI patients with ongoing ischemia or large thrombus burden when PCI is planned. They do not replace dual antiplatelet therapy; DAPT plus anticoagulation remains the core, with GP IIb/IIIa inhibitors acting as an adjunct in the cath lab or in select medical scenarios. They are not universally contraindicated in all ACS; only in the presence of certain contraindications such as active major bleeding or severe thrombocytopenia.